title: Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer.
abstract: OBJECTIVE
  To study the roles of βIII-tubulin and survivin in the development of gastric cancer, and see for any relationship between the expression levels of these two genes and docetaxel chemoresistance in advanced gastric cancer.
  
  
  METHODS
  Patients with advanced gastric cancer treated with docetaxel-based chemotherapy were enrolled and their tumor samples were collected retrospectively for analysis (study group). The control group consisted of patients with benign gastric mucosa lesions. Expression levels of βIII-tubulin and survivin were evaluated with immunohistochemistry.
  
  
  RESULTS
  The expression levels of βIII-tubulin and survivin in the study group were significantly higher compared with those in the control group (p<0.01). Spearman's correlation analysis suggested that the expression of βIII-tubulin was also correlated with that of survivin (p<0.05), but no correlation existed between the expression levels of βIII-tubulin and survivin with age, gender and pathological tumor type. The complete response (CR) + partial response (PR) rates were 54.10%. Patients with βIII-tubulin and/or survivin overexpression were less responsive to docetaxel-based therapy (p<0.05) and also had shorter median time to progression and 1- and 2-year survival rates (p<0.05).
  
  
  CONCLUSIONS
  Overexpression of βIII-tubulin and survivin in gastric cancer cells was associated with resistance to docetaxel-based chemotherapy in patients with advanced gastric cancer.
authors: The Third Affiliated Hospital, Wenzhou Medical College, Wenzhou, China. zhengweie@sohu.com
authors: Wei-e
authors: WE
authors: Zheng
authors: Hua
authors: H
authors: Chen
authors: Shao-fei
authors: SF
authors: Yuan
authors: Li-li
authors: LL
authors: Wu
authors: Wu
authors: W
authors: Zhang
authors: Hong-yu
authors: HY
authors: Sun
authors: Wen-jun
authors: WJ
authors: Chen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000556:secondary; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality / Q000556:secondary; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality / Q000556:secondary; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality / Q000556:secondary; D016022:Case-Control Studies; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D000077022:Survivin; D043823:Taxoids / Q000008:administration & dosage; D014404:Tubulin / Q000378:metabolism*; D055815:Young Adult
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; C498585:TUBB3 protein, human; D043823:Taxoids; D014404:Tubulin; D000077143:Docetaxel; D002955:Leucovorin; D005472:Fluorouracil